Page last updated: 2024-12-06

pivalyloxymethyl butyrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pivalyloxymethyl butyrate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60748
CHEMBL ID100014
SCHEMBL ID356482
MeSH IDM0191821

Synonyms (31)

Synonym
37380-45-3
an 9 (ion exchanger)
122110-53-6
an-9
pivanex
((2,2-dimethylpropanoyl)oxy)methyl butanoate
brn 4861411
pivalyloxymethyl butyrate
an 9
butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester
butanoyloxymethyl 2,2-dimethylpropanoate
butyric acid 2,2-dimethyl-propionyloxymethyl ester
CHEMBL100014
butyric acid 2,2-dimethyl-propionyloxymethyl ester(an9)
unii-55vnk5440p
55vnk5440p ,
pivaloyloxymethyl butyrate
pivaloyloxymethylbutyrate
SCHEMBL356482
an-9;pivalyloxymethyl butyrate
J-004762
an-9, >=95% (hplc)
DTXSID40190818
(pivaloyloxy)methyl butyrate
AKOS030571025
DB05103
HY-120508
Q27261343
CS-0078203
BS-51881
F72881

Research Excerpts

Overview

Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid.

ExcerptReferenceRelevance
"Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid. "( Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Honma, Y; Kasukabe, T; Niitsu, N; Okabe-Kado, J; Umeda, M; Yamamoto-Yamaguchi, Y; Yokoyama, A, 2000
)
2.02

Compound-Compound Interactions

ExcerptReferenceRelevance
" The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas."( In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Entin-Meer, M; Haas-Kogan, DA; Lamborn, KR; Nudelman, A; Rephaeli, A; VandenBerg, SR; Yang, X, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID41063Lethal dose was determined1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41064Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 100 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID247711Concentration required for 50% inhibition of human HL-60 cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID154429Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID41070Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 12.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID234601T/C value was determined1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID247690Concentration required for 50% inhibition of human PC-3 cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID41061Effect on appearance of B16F10.9 colonies in semisolid agar1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41069Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 100 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID247712Concentration required for 50% inhibition of human HT-29 cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID81447Concentration required for 50% proliferation inhibition of human promyelocytic HL-60 cell line1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41066Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 25 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID247800Concentration required for 50% inhibition of human HL-60 MX2 cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID247742Concentration required for 50% inhibition of human MES-SA cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID41065Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 12.5 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41062Inhibitory activity on growth of B16F10.9 melanoma cell line1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID217956Concentration required for 50% proliferation inhibition of myelomonocytic WEHI cell line1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41068Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) was observed after administration of 50 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41072Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID41071Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 25 mg/kg dose1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Novel anticancer prodrugs of butyric acid. 2.
AID3329Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID247759Concentration required for 50% inhibition of human MES-DX5 cell proliferation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (31.03)18.2507
2000's18 (62.07)29.6817
2010's1 (3.45)24.3611
2020's1 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.67%)5.53%
Reviews3 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]